Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
Saved in:
| Title: | Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. |
|---|---|
| Authors: | Fitzpatrick O; Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland., Naidoo J; Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21231, USA. |
| Source: | Lung Cancer (Auckland, N.Z.) [Lung Cancer (Auckl)] 2021 Nov 02; Vol. 12, pp. 123-131. Date of Electronic Publication: 2021 Nov 02 (Print Publication: 2021). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101632521 Publication Model: eCollection Cited Medium: Print ISSN: 1179-2728 (Print) Linking ISSN: 11792728 NLM ISO Abbreviation: Lung Cancer (Auckl) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1179-2728 |
|---|---|
| DOI: | 10.2147/LCTT.S305466 |
